Table 1.
Baseline characteristic of study patients in the gastric ulcer and duodenal ulcer studiesa
| Characteristic | GU study | DU study | ||||
|---|---|---|---|---|---|---|
| Vonoprazan | Lansoprazole | Total | Vonoprazan | Lansoprazole | Total | |
| (N = 244) | (N = 238) | (N = 482) | (N = 184) | (N = 188) | (N = 372) | |
| Age (years), mean (s.d.) | 58.2 (13.2) | 58.6 (13.5) | 58.4 (13.3) | 49.9 (14.6) | 50.2 (14.8) | 50.0 (14.7) |
| Male, n (%) | 163 (66.8) | 170 (71.4) | 333 (69.1) | 125 (67.9) | 120 (63.8) | 245 (65.9) |
| Height (cm), mean (s.d.) | 163.5 (9.7) | 163.8 (9.0) | 163.7 (9.4) | 164.9 (8.9) | 164.6 (9.8) | 164.8 (9.3) |
| Weight (kg), mean (s.d.) | 59.6 (11.6) | 60.6 (12.1) | 60.1 (11.8) | 63.0 (12.5) | 62.2 (12.8) | 62.6 (12.6) |
| BMI (kg/m2), Mean (s.d.) | 22.2 (3.5) | 22.5 (3.5) | 22.3 (3.5) | 23.1 (3.6) | 22.8 (3.5) | 23.0 (3.6) |
| NSAID/low‐dose aspirin use, n (%) | ||||||
| Yes, stopped before Visit 1 | 16 (6.6) | 17 (7.1) | 33 (6.8) | 14 (7.7) | 11 (5.9) | 25 (6.7) |
| Yes, ongoing | 20 (8.2) | 28 (11.8) | 48 (10.0) | 13 (7.1) | 17 (9.0) | 30 (8.1) |
| No | 208 (85.2) | 193 (81.1) | 401 (83.2) | 156 (85.2) | 160 (85.1) | 316 (85.2) |
| Helicobacter pylori positive, n (%) | 208 (85.2) | 191 (80.3) | 399 (82.8) | 152 (83.1) | 141 (75.8) | 293 (79.4) |
| CYP2C19 genotype, n (%) | ||||||
| Homozygous EM (*1/*1) | 94 (39.7) | 90 (38.0) | 184 (38.8) | 61 (33.9) | 60 (32.4) | 121 (33.2) |
| Heterozygous EM (*1/*2, *1/*3) | 102 (43.0) | 114 (48.1) | 216 (45.6) | 89 (49.4) | 89 (48.1) | 178 (48.8) |
| PM (*2/*2, *2/*3, *3/*3) | 41 (17.3) | 33 (13.9) | 74 (15.6) | 30 (16.7) | 36 (19.5) | 66 (18.1) |
| Current ulcers: number, n (%) | ||||||
| Single | 201 (82.4) | 175 (73.5) | 376 (78.0) | 136 (74.3) | 134 (71.3) | 270 (72.8) |
| Multiple | 43 (17.6) | 63 (26.5) | 106 (22.0) | 47 (25.7) | 54 (28.7) | 101 (27.2) |
| Current ulcers: shape, n (%) | ||||||
| Circular | 82 (33.6) | 106 (44.5) | 188 (39.0) | 69 (37.7) | 63 (33.5) | 132 (35.6) |
| Oval | 136 (55.7) | 106 (44.5) | 242 (50.2) | 95 (51.9) | 93 (49.5) | 188 (50.7) |
| Other | 26 (10.7) | 26 (10.9) | 52 (10.8) | 19 (10.4) | 32 (17.0) | 51 (13.7) |
| Current ulcers: size, n (%) | ||||||
| Smaller than 5 mm | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (0.5) | 0 (0.00) | 1 (0.3) |
| 5–10 mm | 116 (47.5) | 104 (43.7) | 220 (45.6) | 134 (73.2) | 130 (69.1) | 264 (71.2) |
| 10–20 mm | 86 (35.2) | 95 (39.9) | 181 (37.6) | 43 (23.5) | 52 (27.7) | 95 (25.6) |
| 20–30 mm | 29 (11.9) | 28 (11.8) | 57 (11.8) | 5 (2.7) | 2 (1.1) | 7 (1.9) |
| Larger than 30 mm | 13 (5.3) | 11 (4.6) | 24 (5.0) | 0 (0.0) | 4 (2.1) | 4 (1.1) |
| Ulcer history, n (%) | ||||||
| First episode | 154 (63.1) | 133 (55.9) | 287 (59.5) | 95 (51.9) | 92 (48.9) | 187 (50.4) |
| Recurrence | 90 (36.9) | 105 (44.1) | 195 (40.5) | 88 (48.1) | 96 (51.1) | 184 (49.6) |
BMI, body mass index; CYP2C19, cytochrome P450 2 C19; DU, duodenal ulcer; EM, extensive metaboliser; GU, gastric ulcer; NSAID, nonsteroidal anti‐inflammatory drug, PM, poor metaboliser, s.d., standard deviation.
a
This analysis includes patients who were randomised to study treatment.